Physician profile
Gregory Ochsner
NPI 1689660011
$9,737.66
in general payments reported to CMS, 2019-2025
41 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 84% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $5,895 · 2021: $741 · 2022: $158 · 2023: $523 · 2024: $1,117 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,659.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $6,506.57 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $301.18 | 2019-2025 | |
| Janssen Biotech, INC. | $257.80 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Novartis Pharmaceuticals Corporation | $226.50 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $183.01 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $168.69 | 2019-2025 | Vyloy |
| Alexion Pharmaceuticals, INC. | $168.60 | 2024-2025 | Ultomiris |
| Siemens Medical Solutions USA, INC. | $157.65 | 2024 | Varian Ethos Treatment Planning |
| Pfizer INC. | $121.71 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $120.63 | 2021 | |
| Eisai INC. | $114.42 | 2023-2025 | |
| Genmab U.S., INC. | $103.39 | 2024-2025 | Tivdak |
| Takeda Pharmaceuticals U.S.A., INC. | $95.57 | 2023-2024 | Ninlaro, Fruzaqla, Iclusig |
| Aveo Pharmaceuticals, INC. | $95.10 | 2025 | |
| Incyte Corporation | $90.77 | 2024-2025 | Monjuvi, Pemazyre, Jakafi |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ochsner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.